DOCSLIB.ORG

Introduction of Ertapenem Into a Hospital Formulary: Effect on Antimicrobial Usage and Improved in Vitro Susceptibility of Pseudomonas Aeruginosaᰔ Ellie J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction of Ertapenem Into a Hospital Formulary: Effect on Antimicrobial Usage and Improved in Vitro Susceptibility of Pseudomonas Aeruginosaᰔ Ellie J ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2009, p. 5122–5126 Vol. 53, No. 12 0066-4804/09/$12.00 doi:10.1128/AAC.00064-09 Copyright © 2009, American Society for Microbiology. All Rights Reserved. Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosaᰔ Ellie J. C. Goldstein,1,2* Diane M. Citron,1 Victoria Peraino,3 Tanya Elgourt,4 Anne R. Meibohm,5 and Shuang Lu5 RM Alden Research Laboratory, Santa Monica, California1; Departments of Infectious Diseases,2 Microbiology,3 and Pharmacy,4 St. Johns’ Health Center, Santa Monica, California 90404; and Merck & Co., Inc., North Wales, Pennsylvania5 Received 16 January 2009/Returned for modification 2 July 2009/Accepted 21 September 2009 After ertapenem was added to the formulary of a 344-bed community teaching hospital, we retrospectively studied its effect on antimicrobial utilization and on the in vitro susceptibility of various antimicrobial agents against Pseudomonas aeruginosa. Three study periods were defined as preintroduction (months 1 to 9), postin- Downloaded from troduction but before the autosubstitution of ertapenem for ampicillin-sulbactam (months 10 to 18), and after the policy of autosubstitution (months 19 to 48) was initiated. Ertapenem usage rose slowly from introduction to a range of 36 to 48 defined daily doses/1,000 patient days (DDD) with a resultant decrease in ampicillin- sulbactam usage due to autosubstitution. Imipenem usage peaked 6 months after the introduction of ertap- enem and started to decline coincidently with the increased use of ertapenem. During the second period, -Prior to the introduction of ertapenem, the suscepti .(0.002 ؍ ؊1.28; P؍ imipenem usage decreased (slope bility of P. aeruginosa to imipenem increased from 61 to 81% at month 7 but then decreased slightly to 67% at aac.asm.org month 9. After the introduction of ertapenem, susceptibility continued to increase; the increasing trend was P < 0.001). In the third period, the median susceptibility (interquartile range) was ;1.74 ؍ significant (slope 88% (82 to 95%). This change appeared related to decreased imipenem usage. For every unit decrease in the in the susceptibility of P. aeruginosa at IOWA STATE UNIV on January 23, 2010 (0.008 ؍ monthly DDD of imipenem, there was an increase of 0.38% (P to imipenem in the same month. Ertapenem was effective in our antimicrobial stewardship program and may have helped improve the P. aeruginosa antimicrobial susceptibility to imipenem by decreasing the unnecessary usage and selective pressure of antipseudomonal agents. The development of multidrug-resistant gram-negative stable ␤-lactams like ertapenem (15, 18). The FDA approved pathogens driven by antimicrobial selective pressures has be- ertapenem, a carbapenem (19) without Pseudomonas aerugi- come an increasing concern in hospitalized patients (1, 14, 16). nosa activity, for use against community-acquired pneumonia, For Enterobacteriaceae, ␤-lactamases such as the extended- complicated intraabdominal infections, pelvic infections, com- spectrum ␤-lactamases (ESBLs) and plasmid and chromo- plicated urinary tract infections, and skin and soft-tissue infec- somal AmpCs are probably the most important resistance tions, including diabetic foot infections. However, concern as mechanisms, although other extended-spectrum class A en- to whether ertapenem might adversely affect the activity of the zymes, such as KPC, also are emerging (1). For P. aeruginosa, carbapenems imipenem and meropenem against P. aeruginosa chromosomal AmpC, permeability changes (OprD), and the has been a barrier for its use. multidrug efflux pumps are probably the determining factors. Studies performed prior to ertapenem’s approval attempted Metallo-␤-lactamases are distinctly unusual in Enterobacteria- to define risk factors for Pseudomonas resistance (6, 11). Lau- ceae and P. aeruginosa in the United States but are a more tenbach et al. (11) found not only a higher mortality rate important problem in other geographic areas (10). The devel- (31.1%) for patients infected with an imipenem-resistant P. opment, spread, and persistence of these resistance mecha- aeruginosa than for those infected with imipenem-susceptible nisms complicates the selection of antimicrobial therapy when strains (16.7%) but also concluded that the only independent trying to avoid the increased selective pressures caused by the risk factor for imipenem resistance was fluoroquinolone use. utilization of any one class of antimicrobial agents. Conse- Fortaleza et al. (6) evaluated the problem of P. aeruginosa quently, the Infectious Diseases Society of America has issued resistance and concluded that imipenem, amikacin, and van- guidelines to enhance antimicrobial stewardship programs (4), comycin use were associated with imipenem-resistant P. aerugi- with goals that include minimizing the emergence of resistance nosa. Patterson (16) has reviewed the various conflicting stud- by the appropriate use of antimicrobials. ies of this topic and concludes that “the lack of alternative The increased importance of ESBL resistance in Escherichia agents on the horizon that are active against gram-negative coli and Klebsiella species has necessitated the use of ESBL- bacteria makes our efforts at controlling emergence of resis- tance all the more imperative.” Because we felt the addition of ertapenem to our formulary would have cost savings and clin- * Corresponding author. Mailing address: 2021 Santa Monica Blvd., ical utility but were concerned about collateral damage, we Suite 740 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: [email protected]. retrospectively studied the effect of the addition of ertapenem ᰔ Published ahead of print on 28 September 2009. on antimicrobial utilization and on the in vitro activity of imi- 5122 VOL. 53, 2009 INTRODUCTION OF ERTAPENEM INTO HOSPITAL FORMULARY 5123 TABLE 1. Usage of ertapenem and imipenem and susceptibility of P. aeruginosa to imipenem Susceptibility (%) of P. aeruginosa Ertapenem usage (DDD) Imipenem usage (DDD) to imipenem Period Months Percentilea Percentilea Percentilea Range Range Range 25 50 75 25 50 75 25 50 75 Prior to ertapenem usage 0–9 0 0 0 0 25 30 34 13–40 62 69 77 60–81 After addition of ertapenem 10–19 7 8 20 5–35 28 35 43 23–59 71 75 82 63–91 to formulary After policy substitution 20–48 39 44 53 24–79 22 25 29 13–50 82 88 95 67–100 a 50th percentile is the median; 25th and 75th percentiles are the first and third quartiles (interquartile range), respectively. penem, ertapenem, levofloxacin, cefepime, tobramycin, and RESULTS piperacillin-tazobactam on P. aeruginosa. (Parts of this study were presented previously at the 44th Table 1 and Fig. 1 show the monthly usage (DDD) of imi- Annual Meeting of the Infectious Diseases Society of America, penem and ertapenem and the susceptibility of P. aeruginosa to Downloaded from Toronto, Canada, 2006 [3].) imipenem during the 48 months of observation. The usage of ertapenem increased slowly from its introduction to the for- mulary in month 10 through month 15 (DDD ϭ 8), and then MATERIALS AND METHODS usage increased more sharply. Prior to the implementation of Study design. We retrospectively collected and analyzed data on the antimi- the policy of autosubstituting ertapenem for ampicillin-sulbac- crobial usage (defined daily dose/1,000 patient days [DDD]) and antimicrobial susceptibility for P. aeruginosa in a 344-bed community teaching hospital from tam, the DDD was 35. Subsequently through month 42, usage aac.asm.org January 2002 to December 2005. The hospital has a 51-bed oncology unit that is was relatively consistent, generally in the range of 36 to 48 DDD. involved in research programs, a 32-bed intensive care unit, and a 32-bed step- Toward the end of the observation period (months 43 to 48), down unit. The average daily census for the study period was approximately 200; ertapenem usage increased and then began to decrease again. the average length of stay varied from 4.6 to 9.1 days, with an average stay of 5 In the 9 months of observation prior to the introduction of days, excluding newborns and outliers. Ertapenem was added to the formulary in at IOWA STATE UNIV on January 23, 2010 September 2002, and in July 2003 a policy of autosubstituting ertapenem for ertapenem, the usage of imipenem increased significantly (13 ampicillin-sulbactam was instituted because of increased (40%) E. coli resistance to 39 DDD; slope ϭ 3.18; P Ͻ 0.001). Imipenem usage peaked to ampicillin-sulbactam and because of its relatively high cost. (Ampicillin-sul- in month 15 (DDD ϭ 59) and then started to decline (the slope ϳ bactam was $45/day, not including nursing and pharmacy time or the bag and during the second period was Ϫ1.28; P ϭ 0.002), which is intravenous administration setup materials for three to four daily administra- tions, while ertapenem was ϳ$45/day with one administration per day). The coincident in time with the sharper increase in the use of policy of reminding physicians to voluntarily substitute cefotaxime for cefepime ertapenem. Overall, usage declined significantly during the if no P. aeruginosa was isolated from cultures after 72 h of empirical therapy was second period (the change of slope was Ϫ4.46; P Ͻ 0.001). continued. No other antimicrobial-prescribing restrictions were instituted, and During the third period, imipenem usage was relatively con- no other new agents were added to the formulary during the study period. No unusual infection control measures were instituted during this period. stant, generally between 22 and 29 DDD. Contrary to the trend Statistical analysis. To investigate the trends in antibiotic usage in the sus- of increasing the use of imipenem prior to the introduction of ceptibility of P. aeruginosa, we first defined three periods in the 48-month study. ertapenem, there was a significant decrease in the use of imi- The first period, months 1 to 9, was prior to the introduction of ertapenem to the penem when ertapenem became available.
Load more

Recommended publications
  • Penicillin Skin Testing
    Penicillin Skin Testing Penicillin Skin Testing: Frequently Asked Questions Benzylpenicilloyl Polylysine (Pre-Pen®) and Diluted Penicillin G June 2012 VA Pharmacy Benefits Management Services, Medical Advisory Panel and VISN Pharmacist Executives Benzylpenicilloyl polylysine (Pre-Pen®) was FDA approved in 2009 for the assessment of sensitization to penicillin in those patients suspected, based upon previous experience, of having a clinical hypersensitivity to penicillin. Penicillin skin testing is the most reliable way to evaluate patients for IgE-mediated penicillin allergy. Skin testing is conducted using benzylpenicilloyl polylysine (major determinant), penicillin G diluted with normal saline to 10,000 units/ml (minor determinant), a positive and negative control. Testing with both the major and minor determinant of penicillin can identify up to 97% of patients with an immediate hypersensitivity to penicillin. The intent of this document is to help guide appropriate use of penicillin skin testing. 1. WHEN IS PENICILLIN SKIN TESTING INDICATED? Penicillin skin testing can be considered in those patients with a prior history of hypersensitivity to penicillin or allergy to penicillin in situations where the provider considers penicillin the drug of choice or prefers treatment with penicillin. If skin testing is indicated, the patient should be referred to a VA Allergy Specialist or other appropriately trained physician who is experienced in the application and interpretation of PCN skin testing, as locally designated. Although approximately 10% of patients will remain allergic to penicillin their entire lives, a large majority will stop expressing penicillin-specific IgE-mediated antibodies and can be safely treated with penicillin. Skin testing with benzylpenicilloyl polylysine is contraindicated in patients who are known to be extremely hypersensitive to penicillin and in those patients who have experienced a systemic or marked local reaction to prior administration of benzylpenicilloyl polylysine.
    [Show full text]
  • Empiric Treatment with Antibiotic Combination Therapy Compared with Monotherapy for Adult Patients with Septic Shock of Unknown
    REPORT 2020 SYSTEMATIC REVIEW: Empiric treatment with antibiotic combination therapy compared with monotherapy for adult patients with septic shock of unknown pathogen and origin Utgitt av Norwegian Institute of Public Health Division for Health Services Title Empiric treatment with antibiotic combination therapy compared with monotherapy for adult patients with septic shock of unknown pathogen and origin: a systematic review Norwegian title Hva er effekten av empirisk kombinasjonsbehandling med antibiotika sammen- lignet med monoterapi for voksne pasienter med septisk sjokk forårsaket av ukjent patogen og ukjent opprinnelse: en systematisk oversikt Responsible Camilla Stoltenberg, Director General Authors Jan PW Himmels, project leader, seniorrådgiver, Norwegian Institute of Public Health Gunn Elisabeth Vist, seniorforsker, Norwegian Institute of Public Health Liv Giske, seniorforsker, Norwegian Institute of Public Health Eva Helene Arentz-Hansen, seniorforsker, Norwegian Institute of Public Health Gyri Hval, bibliotekar, Norwegian Institute of Public Health ISBN 978-82-8406-084-2 Project number RL035 Type of report Systematic Review No. of pages 26 (32 inklusiv vedlegg) Client Helsedirektoratet Subject Septic shock, antibiotic dual treatment, antibiotic monotherapy, antimicrobi- heading(MeSH) otic ressistance (AMR) Citation Himmels JPW, Vist GE, Giske L, Arentz-Hansen EH, Hval G. Empiric treatment with antibiotic combination therapy compared with monotherapy for adult patients with septic shock of unknown pathogen and origin: a systematic
    [Show full text]
  • Mechanisms of Β- Lactamase Inhibition And
    MECHANISMS OF β- LACTAMASE INHIBITION AND HETEROTROPIC ALLOSTERIC REGULATION OF AN ENGINEERED β- LACTAMASE-MBP FUSION PROTEIN By WEI KE Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy. Dissertation Advisor: Dr. Focco ven den Akker Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY May, 2011 CASE WESTERN RESERVE UNVERISTY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Wei Ke . candidate for the Ph.D degree*. (signed)Paul Carey . (chair of the committee) Focco van den Akker . Menachem Shoham . Robert A. Bonomo . Marion Skalweit . ___________________________________________ (date) 23 March, 2011 *We also certify that written approval has been obtained for any proprietary material contained therein. TABLE OF CONTENTS LIST OF TABLES ………………………………………………………………………8 LIST OF FIGURES ………………………………...…………………………………9 ACKNOWLEDGEMENTS ...………………………………………………………..13 LIST OF ABBREVIATIONS …………………...……………………………………15 ABSTRACT ……………………………….………………………………………...17 CHAPTER 1 Background and Significance …………………………………………....18 1.1 Antibiotic Resistance Crisis……………….…………………………….…...18 1.2 β-lactamases overview……………………………………………………….19 1.3 β-Lactam antibiotics and β-lactamase inhibitors ……………………………23 1.4 Structures of class A β –lactamases …………………………………………25 CHAPTER 2 Crystal Structures of SHV-1 β-Lactamase in Complex with Boronic Acid Transition State Inhibitors …………………………………………………...…….32 2.1 Introduction ………………………………………………………………….32 2.2 Materials and Methods ………………………………………………….…...34 2.2.1.
    [Show full text]
  • Nethmap-Maran 2014
    NethMap 2014 MARAN 2014 Consumption of antimicrobial agents and Monitoring of Antimicrobial Resistance antimicrobial resistance among and Antibiotic Usage in Animals medically important bacteria in the Netherlands in 2013 in the Netherlands Autoriteit Diergeneesmiddelen Autoriteit Diergeneesmiddelen Autoriteit Diergeneesmiddelen Autoriteit Diergeneesmiddelen PART 1: NethMap 2014 pg 1 - 98 Part 2: MARAN 2014 pg 1 - 68 NethMap 2014 Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in The Netherlands in 2013 June 2014 NethMap 2014 1 Colophon This report is published under the acronym NethMap by the SWAB, the Dutch Foundation of the Working Party on Antibiotic Policy, in collaboration with the Centre for Infectious disease control (CIb) of the RIVM, the National Institute for Public Health and the Environment of the Netherlands. SWAB is fully supported by a structural grant from CIb, on behalf of the Ministry of Health, Welfare and Sports of the Netherlands. The information presented in NethMap is based on data from ongoing surveillance systems on the use of antimicrobial agents in human medicine and on the prevalence of resistance to relevant antimicrobial agents among medically important bacteria isolated from healthy individuals and patients in the community and from hospitalized patients. The document was produced on behalf of the SWAB by the Studio of the RIVM. NethMap can be ordered from the SWAB secretariat, c/o Secretariaat SWAB p/a Universitair Medisch Centrum St Radboud Medische Microbiologie, Huispost 777, route 777 Postbus 9101, 6500 HB Nijmegen, Tel.: (024) 36 19041/14356 or by email to [email protected]. NethMap 2014 and earlier versions are also available from the website of the SWAB: www.swab.nl.
    [Show full text]
  • From Clostridium Butyricum
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1989, p. 1302-1307 Vol. 33, No. 8 0066-4804/89/081302-06$02.00/0 Copyright © 1989, American Society for Microbiology Purification and Characterization of a New r-Lactamase from Clostridium butyricum TADATAKA KESADO, LENNART LINDQVIST, MARIA HEDBERG, KAJSA TUNER, AND CARL ERIK NORD* Department of Microbiology, Huddinge University Hospital, Karolinska Institute, S-141 86 Huddinge, and National Bacteriological Laboratory, S-105 21 Stockholm,* Sweden Received 9 December 1988/Accepted 23 May 1989 A highly penicillin-resistant j-lactamase-producing strain of Clostridium butyricum, strain NBL 3, was isolated. The specific activity of the unpurified ,I-lactamase was 0.29 U/mg of protein. The enzyme was purified 1,130-fold by QAE Zetaprep, Sephacryl S-300, and Mono Q column passages. The purified enzyme was judged homogeneous by sodium dodecyl sulfate gradient gel electrophoresis and fast protein liquid chromatography. The enzyme hydrolyzed phenoxymethylpenicillin, benzylpenicillin, ampicillin, and carbenicillin more rapidly than piperacillin and cephaloridine. Cephalothin, cephalexin, cefoxitin, moxalactam, cefotaxime, and imi- penem were only slightly hydrolyzed, at less than 1% the rate for phenoxymethylpenicillin. The enzyme was inhibited by clavulanic acid, sulbactam, tazobactam, and p-chloromercuribenzoate. The molecular weight was determined by gel filtration and sodium dodecyl sulfate gradient gel electrophoresis to be 32,000. The isoelectric point was 4.4. Aspartic acid-asparagine, glutamic acid-glutamine, leucine, lysine, alanine, and serine dominated the amino acid composition. Several investigators have reported that Bacteroides fra- late log phase (18 h) by centrifugation at 10,000 x g for 30 gilis and closely related species produce ,-lactamases with min at 4°C.
    [Show full text]
  • Swedres-Svarm 2014
    2014 SWEDRES|SVARM Consumption of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2014 A report on Swedish Antibiotic Utilisation and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Jenny Hellman and Olov Aspevall, Public Health Agency of Sweden Björn Bengtsson and Märit Pringle, National Veterinary Institute Addresses: Public Health Agency of Sweden SE-171 82 Solna, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se ISSN 1650-6332 ISBN 978-91-7603-360-9 (pdf) ISBN 978-91-7603-361-6 (print) Article no. at Folkhälsomyndigheten 14027 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/publicerat-material/ or www.sva.se. The title can also be ordered from the webshop at: www.folkhalsomyndigheten.se/publicerat-material/ or Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute, SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] Text and tables may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2014. Consumption of antibiotics and occurrence of antibiotic resistance in Sweden.
    [Show full text]
  • Antibiotic Prescribing – Quality Indicators
    Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006 Antibiotic prescribing – quality indicators P1460 Methods: Medical records from all patients with positive blood Is self-medication with antibiotics in Europe cultures in 2001 were analysed retrospectively. Factors driven by prescribed use? predisposing to infections, results of blood cultures, antibiotic use, and outcome were recorded. L. Grigoryan, F.M. Haaijer-Ruskamp, J.G.M. Burgerhof, Results: The antibiotic use in 226 episodes of true bacteraemia J.E. Degener, R. Deschepper, D. Monnet, A. Di Matteo, were analysed. According to guidelines empirical antibiotic ˚ and the SAR E.A. Scicluna, A. Bara, C. Stalsby Lundborg, J. Birkin treatment should be adjusted in 166 episodes. Antibiotic use was group adjusted in 146 (88%) of these 166 episodes, which led to a Objectives: The occurrence of self-medication with antibiotics narrowing of therapy in 118 (80%) episodes. Compared to has been described in the US and Europe, a possible empirical therapy there was a 22% reduction in the number of contributing factor to increased antibiotic resistance. An antibiotics. Adjustment of therapy was more often performed in important reason for using self-medication can be past Gram-negative bacteraemia and polymicrobial cultures than in experience with antibiotics prescribed by health professionals. Gram-positive bacteraemia. In bacteraemia caused by We investigated whether self-medication in Europe follows the ampicillin-resistant E. coli, ampicillin was mostly replaced by same pattern as prescribed use. ciprofloxacin. The cost for 7 days adjusted therapy was 19800 Methods: A population survey was conducted in: North and EUR (23%) less than for 7 days of empirical therapy.
    [Show full text]
  • Antibiotic Stewardship Support Through Penicillin Allergy Testing: a POCKET GUIDE
    Antibiotic stewardship support through penicillin allergy testing: A POCKET GUIDE Second Edition 1 2 Support optimal antibiotic use Antibiotic resistance is a clinical and public health crisis. The misuse of antibiotics is a primary driver of this issue and antibiotic stewardship programs are challenged to change clinical practice patterns in response to this growing problem. This guide provides a practical overview of implementing penicillin allergy skin testing as a key component of stewardship efforts. Penicillin allergy skin testing is a novel approach to address the misuse of antibiotics and supports optimal antibiotic utilization.1 Evaluation and diagnosis of penicillin allergy is recommended in the CDC’s “US Antibiotic Awareness Week” program2, IDSA Stewardship Guidelines3, SHEA 4 Guidelines and is endorsed by the AAAAI. 1 How penicillin allergy impacts antibiotic selection The number of antibiotic-resistant bacteria continues to increase every year.5 The number of antibiotics in the approval pipeline continues to decrease each year.5 The use of antibiotics is the single most important factor leading to antibiotic resistance around the world. Antibiotics are among the most commonly prescribed drugs used in human medicine. 6 2 Up to 50% of all antibiotics prescribed are not needed or are not optimally effective as prescribed.6 23,0000 deaths in the US each year are caused by drug-resistant bacteria.5 3 Know the facts P ENICILLIN ALLERGY Penicillin allergy is the most commonly reported drug allergy.7 Ten percent of the patients in
    [Show full text]
  • Cross-Class Metallo-Β-Lactamase Inhibition by Bisthiazolidines Reveals Multiple Binding Modes
    Cross-class metallo-β-lactamase inhibition by PNAS PLUS bisthiazolidines reveals multiple binding modes Philip Hinchliffea, Mariano M. Gonzálezb, Maria F. Mojicac,d, Javier M. Gonzáleze, Valerie Castillof, Cecilia Saizf, Magda Kosmopouloua, Catherine L. Tookea, Leticia I. Llarrullb, Graciela Mahlerf, Robert A. Bonomoc,d,g,h,i, Alejandro J. Vilab,1, and James Spencera,1 aSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol BS8 1TD, United Kingdom; bFacultad de Ciencias Bioquímicas y Farmacéuticas, Instituto de Biología Molecular y Celular de Rosario Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina, Universidad Nacional de Rosario, 2000 Rosario, Argentina; cResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106; dDepartment of Biochemistry, Case Western Reserve University, Cleveland, OH 44106; eInstituto de Bionanotecnología, Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina, Universidad Nacional de Santiago del Estero, G4206XCP Santiago del Estero, Argentina; fLaboratorio de Química Farmacéutica, Facultad de Química, Universidad de la República, Montevideo 11800, Uruguay; gDepartment of Pharmacology, Case Western Reserve University, Cleveland, OH 44106; hDepartment of Microbiology, Case Western Reserve University, Cleveland, OH 44106; and iDepartment of Molecular Biology, Case Western Reserve University, Cleveland, OH 44106 Edited by Gregory A. Petsko, Weill Cornell Medical College, New York, NY, and approved May 16, 2016 (received for review January 25, 2016) Metallo-β-lactamases (MBLs) hydrolyze almost all β-lactam antibi- molecule (Wat1) bridges/coordinates Zn1 and Zn2 in an arrange- otics and are unaffected by clinically available β-lactamase inhibi- ment that is suited to activate it as a nucleophile. tors (βLIs).
    [Show full text]
  • Critical Evaluation of Ceftolozane–Tazobactam for Complicated Urinary Tract and Intra-Abdominal Infections
    Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Year: 2016 Volume: 12 Therapeutics and Clinical Risk Management Dovepress Running head verso: Giancola et al Running head recto: Ceftolozane–tazobactam for cUTIs and cIAIs open access to scientific and medical research DOI: http://dx.doi.org/10.2147/TCRM.S83844 Open Access Full Text Article REVIEW Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections Stephanie E Giancola1 Abstract: The rise in resistant Gram-negative pathogens continues to challenge clinicians treating Monica V Mahoney2 infections. These resistant infections have inspired the development of new antimicrobial agents, Tiffany E Bias3,4 including ceftolozane–tazobactam, a novel β-lactam/β-lactamase inhibitor combination approved Elizabeth B Hirsch2,5 by the US Food and Drug Administration for the treatment of complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) in combination with metronidazole. 1Department of Pharmacy, St Mary’s Medical Center, Huntington, WV, 2Beth Ceftolozane exhibits bactericidal activity by inhibiting penicillin-binding proteins (PBPs), with Israel Deaconess Medical Center, high affinity for PBP1b, PBP1c, and PBP3. The addition of tazobactam protects ceftolozane 3 Boston, MA, Hahnemann University from hydrolysis by irreversibly binding to some β-lactamase enzymes. Ceftolozane–tazobactam Hospital, 4Drexel University College of Medicine, Philadelphia, PA, is active against a wide range of Gram-negative pathogens, including extended-spectrum 5 For personal use only. Department of Pharmacy and Health β-lactamase (ESBL)-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas Systems Sciences, Northeastern aeruginosa, several streptococcal species, and Bacteroides fragilis. When anaerobic coverage is University, Boston, MA, USA needed, it should be used in combination with metronidazole.
    [Show full text]
  • Swedres-Svarm 2016
    2016 SWEDRES|SVARM Consumption of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2016 A report on Swedish Antibiotic Utilisation and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Jenny Hellman and Olov Aspevall, Public Health Agency of Sweden Björn Bengtsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden SE-171 82 Solna, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text and tables may be cited and reprinted only with reference to this report. Images, photographs and illustrations are pro- tected by copyright. Suggested citation: Swedres-Svarm 2016. Consumption of antibiotics and occur- rence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 16124 This title and previous Swedres and Svarm reports are avail- able for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2016 as a pdf in publicerat-material/ or at www.sva.se your mobile device, for reading and sharing. Download a free QR code reader in the App Store for Apple Layout: ETC kommunikation devices or in Google Play for Android, for example Quick Scan QR Code Reader (iPhone) or QR Droid Code Scanner Print: Taberg Media Group, Taberg 2017 (Android).
    [Show full text]
  • Four Enzymes Define the Incorporation of Coenzyme a in Thienamycin Biosynthesis
    Four enzymes define the incorporation of coenzyme A in thienamycin biosynthesis Michael F. Freeman*, Kristos A. Moshos†, Micah J. Bodner†, Rongfeng Li†, and Craig A. Townsend*†‡ Departments of *Biology and †Chemistry, Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218 Edited by Christopher T. Walsh, Harvard Medical School, Boston, MA, and approved June 4, 2008 (received for review May 8, 2008) 2ϩ The enzymatic activities of three proteins encoded by the thien- supported by the dependence on vitamin B12 and Co for amycin gene cluster of Streptomyces cattleya (ThnR, ThnH, and thienamycin production (2, 11). ThnT) have been shown to incrementally cleave CoA to afford the Initial insights into the origin of the thienamycin C-2 side chain active side-chain component of the ␤-lactam antibiotic thienamy- were based on incorporation studies that suggested cysteine was cin. These results supersede proposals based on earlier radiochem- directly incorporated into the carbapenem. [35S]- and ical incorporation experiments. For 20 years it has been thought [U-14C]cystine was shown to give Ͼ70% incorporation into that cysteine was directly incorporated into the antibiotic. Specific, thienamycin, whereas [35S]pantethine was very poorly incorpo- stepwise truncation of CoA to 4-phosphopantetheine, panteth- rated into the antibiotic (9). These feeding studies were carried eine, and finally cysteamine was observed with ThnR, ThnH, and out in response to the discovery of the OA-6129 family of ThnT, respectively, in a series of coupled enzymatic assays. Pan- carbapenems, where an intact pantetheine side chain was ob- tetheinylated carbapenams were synthesized to address possible served in place of cysteamine (12).
    [Show full text]